Plans for Phase 3 smoking cessation trial underway
04 April, 2016Invion has met with the US FDA to discuss Phase 3 plans for development of oral INV102 (nadolol) as a treatment for patients with chronic obstructive pulmonary disease (COPD) who cannot quit cigarette smoking.
Repairing blood vessels to improve anticancer treatment
01 April, 2016A new drug could be used to repair the blood vessel defects that prevent current anticancer treatments from entering tumours.
Wet AMD trial completes patient enrolment
30 March, 2016Opthea has completed patient enrolment in its ongoing phase 1 dose escalation clinical trial of OPT-302 as a novel therapy for wet age-related macular degeneration (wet AMD).
IDT's new manufacturing partner
30 March, 2016WellSpring Pharma Services has agreed to manufacture two to three pharmaceutical products that require manufacturing processes or scale not currently available at IDT's Boronia facilities.
Accelerating anticancer drug discovery
29 March, 2016MecRx has secured a $4 million investment from the Medical Research Commercialisation Fund to advance its breakthrough technology for accelerating drug discovery.
$1 million for radiopharma company
21 March, 2016Clarity Pharmaceuticals is one of 15 lucky companies that this month received grant funding through Accelerating Commercialisation.
Hydrogel to enable tumour-targeting cancer treatment
21 March, 2016Researchers have developed a 3D-printable material that opens the way to personalised cancer treatment by enabling multiple, simultaneous tests to find the correct therapy to target a particular tumour.
Medical cannabis company AusCann to be bought by TWH
18 March, 2016TW Holdings has announced its intention to purchase medical cannabis company AusCann.
Dendrimer technology licensed for herbicide
18 March, 2016Starpharma's Priostar dendrimer technology has been licensed for the development of an enhanced 2,4-D herbicide for the US market.
Hep C drug trial deemed a success
17 March, 2016Shares in Biotron rose almost 60% as the company confirmed positive outcomes from its Phase 2 study of antiviral drug BIT225 in Hepatitis C patients.
POC diagnostics market to reach almost $3 billion by 2021
14 March, 2016GlobalData has projected that the point-of-care (POC) diagnostics market will experience solid growth from $2.13 billion in 2015 to just under $3 billion by 2021, representing a compound annual growth rate (CAGR) of 5.3%.
Innovation fund attracting foreign investment, says fund manager
10 March, 2016The Prime Minister's $500 million innovation fund has already attracted significant international interest and will attract offshore investment to the country, according to life sciences fund manager Jeremy Curnock Cook.
Blood pressure drug boosts the effect of chemo
10 March, 2016Scientists have discovered that a drug developed to treat high blood pressure has a powerful 'chemo-boosting' effect when combined with certain chemotherapeutic drugs for the treatment of angiosarcoma.
Regenerative medicine to treat leg ulcers
09 March, 2016Avita Medical has reported positive results from its multicentre clinical trial of ReGenerCell in the treatment of chronic venous leg ulcers (VLUs).
Second US patent for Australian immunoassay technology
26 February, 2016Adelaide biotechnology company TGR BioSciences has received its second US patent in six months, covering key aspects of the company's CaptSure immunoassay technology.
